Patient Information

REVLIMID® (lenalidomide) is used in the treatment of refractory or relapsed multiple myeloma in patients who have progressive disease. REVLIMID® contains the active ingredient lenalidomide. REVLIMID® belongs to a group of medicines known as antineoplastic (or anticancer) agents. There are many different classes of antineoplastic agents.  REVLIMID® belongs to a class called the IMiD's.

Thalomid® (thalidomide) also belongs to the class of drugs called IMiD’s.  Thalidomide is used in the treatment of both newly diagnosed and refractory or relapsed multiple myeloma patients. It is also used in the treatment of erythema nodosum leprosum (ENL).

 

What is Multiple Myeloma?

Where can I go for other information?

Thalomid® Consumer Medicine Information

REVLIMID® Consumer Medicine Information

Consumer Medicine Information, or CMI, provides clear, easy-to-understand information to consumers and their carers about how to use their medicines.

Consumer Medicine Information leaflets for Celgene products available in Australia are included on this page. Importantly, this information is intended for use in Australia only and does not replace advice from a healthcare professional. You should discuss the Consumer Medicine Information with your healthcare professional if you have any questions or concerns.

Consumer Medicine Information will tell you:

For more information, please contact your doctor or pharmacist.